COVID-19 pandemic has changed the variables of equations of global pharma industry. The current crisis could be a blessing in disguise for Indian Pharma and a valuable opportunity to again become a preferred supplier of pharma products for the world. The Govt of India has cleared a slew of measures to promote manufacturing of APIs and KSMs within the country. There is a potential opportunity for India to truly play the role of “Pharmacy of The World”.
How are Indian Pharma companies penetrating emerging markets? What are the different models of business and how are they addressing various challenges and risks in international markets. To discuss these issues and opportunities for Indian Pharma to leapfrog into the future using the impetus provided by COVID-19, we have invited Mr. Sandeep Joshi,
Country Head of USV Pvt Ltd in Myanmar.
Country Head, Myanmar, USV Pvt Ltd
Mr. Sandeep Joshi is Country Head, Myanmar of USV Pvt Ltd. which is among the top 20 pharma companies in India by value. He has more than 15 years of marketing, commercial and operations experience in cardiac, diabetics and OTC/ Nutritional brands. He has headed marketing for emerging markets at USV. He has deep understanding of regulatory landscapes, policy regulations and its implications across countries of operations including SE Asia, emerging and rest of the world markets. He is adept at launching new brands, handling mature brands and planning sales promotion activities.
2021 - All Rights Reserved.